A Phase 2 interventional study of VLY-686 and Placebo in Treatment-resistant Pruritus Associated With Atopic Dermatitis, sponsored by Vanda Pharmaceuticals. Completed at 5 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Pruritus with a site in Germany — 5 open to participants now, 8 under way, 4 of them phase 3. Pruritus · Germany.
Among the 58 studies in Pruritus with a site in Germany, this one is the 41st largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2013, is one of 17 in phase 2, and was the 14th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →5 of the 58 studies in Pruritus with a site in Germany are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 13 more countries
Ages 12–17
Pfizer · Sites in Germany, United States, Bulgaria and 7 more countries
Ages 18+
Mirum Pharmaceuticals, Inc. · Sites in Germany, Belgium, France and 5 more countries
Ages 2 mo+
Sanofi · Sites in Germany, United States, Argentina and 10 more countries
Ages 18–90
AB Science · Sites in Germany, France, Netherlands and 5 more countries
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 25 · Phase 4 4
First in 2005; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 153 across the 56 interventional studies, 1,580 across the 2 observational. Of the 50 that completed or were terminated, 31 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 58 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 2 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
3 of the studies in Pruritus with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 58 studies in Pruritus with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VLY-686
Drug: Placebo
Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity.
Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left end point was marked "no itch" (0 mm) and in the right end point was marked "worst imaginable itch" (100 mm).
Time frame: 28 days
| Milestone | VLY-686 | Placebo |
|---|---|---|
| Started | 34 | 35 |
| Completed | 30 | 31 |
| Not completed | 4 | 4 |
Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left end point was marked "no itch" (0 mm) and in the right end point was marked "worst imaginable itch" (100 mm).
| mm | VLY-686 | Placebo |
|---|---|---|
| Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. | -40.5 ± 5.30 | -36.5 ± 4.96 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent through study completion (approximately 63 days) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VLY-686 | 0/34 (0%) | 0/34 (0%) | 12/34 (35.3%) |
| Placebo | 0/34 (0%) | 0/34 (0%) | 11/34 (32.4%) |
| Event | VLY-686 | Placebo |
|---|---|---|
| FatigueGeneral disorders | 5/34 | 2/34 |
| HeadacheNervous system disorders | 4/34 | 2/34 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 4/34 | 1/34 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 0/34 | 3/34 |
| DiarrhoeaGastrointestinal disorders | 0/34 | 2/34 |
| DizzinessNervous system disorders | 2/34 | 0/34 |
| Skin burning sensationSkin and subcutaneous tissue disorders | 0/34 | 2/34 |
| Age, Continuous(years) | VLY-686 | Placebo | Total |
|---|---|---|---|
| Mean | 36.6 ± 15.6 | 40.2 ± 14.5 | 38.4 ± 15.1 |
| Sex: Female, Male(Participants) | VLY-686 | Placebo | Total |
|---|---|---|---|
| Female | 19 | 21 | 40 |
| Male | 15 | 14 | 29 |
| Region of Enrollment(participants) | VLY-686 | Placebo | Total |
|---|---|---|---|
| Germany | 34 | 35 | 69 |
| Pruritus 24 hours average intensity Visual Analogue Scale (VAS) at baseline(units on a scale) | VLY-686 | Placebo | Total |
|---|---|---|---|
| Mean | 76.1 ± 9.74 | 77.2 ± 10.87 | 76.6 ± 10.27 |
Ran from Dec 2013 to primary completion in Feb 2015, 14 months.
Results were first posted in Jun 2024, 9 years 3 months after primary completion.
Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 14 months is close to that.
Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant